

PLOS Neglected Tropical Diseases

Congenital syphilis in Argentina: experience in a pediatric hospital

--Manuscript Draft--

Manuscript Number:	PNTD-D-20-00981
Full Title:	Congenital syphilis in Argentina: experience in a pediatric hospital
Short Title:	Congenital Syphilis Retrospective Survey Study
Article Type:	Research Article
Keywords:	Congenital syphilis; asymptomatic infected newborns; bone involvement; late congenital syphilis; serological follow-up
Corresponding Author:	Luciana Noemi García, PhD Hospital de Niños Ricardo Gutiérrez Buenos Aires, Ciudad Autónoma de Buenos Aires ARGENTINA
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Hospital de Niños Ricardo Gutiérrez
Corresponding Author's Secondary Institution:	
First Author:	Luciana Noemi García, PhD
First Author Secondary Information:	
Order of Authors:	Luciana Noemi García, PhD Alejandra Destito Solján Nicolas Falk Nicolas Leonel Gonzalez Griselda Ballering Facundo Garcia Bournissen Guillermo Moscatelli Samanta Moroni Jaime M Altcheh
Order of Authors Secondary Information:	
Abstract:	<p>Although congenital syphilis (CS) is preventable, it is still an important health problem worldwide. Recently, an increase in the number of primary and congenital syphilis cases has been observed. Fetal infection can be particularly aggressive, but newborns can be asymptomatic at birth and run the risk of developing systemic compromise with a poor prognosis.</p> <p>We conducted a study (1987-2019) analyzing the medical records of CS diagnosis cases assisted at the Buenos Aires Children' Hospital. Sixty-one patients were included. Information about demographics, clinical and laboratory findings, T. pallidum serology and treatment was collected. Median age at diagnosis was 2 months (IQ 1-6 months). The distribution of cases showed a bimodal curve, with a peak in 1993 and in 2017. The main clinical findings were: bone alterations in 36/61 (59%); hepatosplenomegaly in 33/61 (54.1%); anemia in 32/51 (62.8%); skin lesions 26/61 (42.6%) and renal compromise in 15/45 (33.3%). Cerebrospinal fluid was studied in 50/61 (81.9%); 5 (10%) were abnormal (reactive VDRL and/or cell alteration count). Only 23 (60.5%) patients had nontreponemal titers fourfold higher than their mothers did. Intravenous penicillin G for an average of 10-14 days was prescribed in 60/61 subjects and one patient received ceftriaxone. Remarkably, only 28 (46%) mothers were tested for syphilis during pregnancy.</p> <p>During follow-up, a decrease in RPR titers was observed reaching seroconversion in 31/34 (91%) subjects at a median of 19.2 months after treatment. Treponemal titers</p>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

	<p>(TPHA) remained reactive.</p> <p>Our results highlighted that an increase in the number of cases of CS is occurring in our population with high morbidity related to delayed diagnosis. A good therapeutic response was observed.</p> <p>CS requires a greater effort from obstetricians to adequately screen for the disease during pregnancy and pediatricians should be alert in order to detect cases earlier, to provide an adequate diagnosis and treatment of CS.</p>
Suggested Reviewers:	<p>Andrés F Henao-Martínez University of Colorado School of Medicine. Aurora, CO, USA andres.henaomartinez@ucdenver.edu</p> <p>Peter Hotez Baylor College of Medicine, Houston, United States hotez@bcm.edu</p> <p>Guilherme Werneck Universidade do Estado do Rio de Janeiro Rio de Janeiro, Brazil guilherme.werneck@terra.com.br</p> <p>Zulfiqar A Bhutta University, Karachi, Pakistan zulfiqar.bhutta@aku.edu</p>
Opposed Reviewers:	
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS NTDs for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p>	<p>This work was funded by financial support of the Hospital de Niños Ricardo Gutiérrez</p>

Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement **will appear in the published article** if the submission is accepted. Please make sure it is accurate. View published research articles from [PLOS NTDs](#) for specific examples.

The authors have declared that no competing interests exist

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

Data Availability

Yes - all data are fully available without restriction

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available

All relevant data are within the manuscript and its Supporting Information files.

<p><i>from (include the name of the third party and contact information or URL).</i></p> <ul style="list-style-type: none">• This text is appropriate if the data are owned by a third party and authors do not have permission to share the data. <p>* typeset</p>	
Additional data availability information:	



Parasitología - Chagas
Hospital de Niños Ricardo Gutiérrez

Centro de Referencia para la Enfermedad de Chagas – Res: 1514/2001



Buenos Aires June 4th, 2020

Shaden Kamhawi

Paul Brindley

Peter J. Hotez

Editors in chief of PLOS Neglected Tropical Diseases

Dear Dr Kamhawi, Dr Aksoy and Dr Hotez,

Re: Manuscript: “Congenital syphilis in Argentina: experience in a pediatric hospital”

Enclosed please find our manuscript, which we ask you to consider for publication in your prestigious Journal.

Congenital syphilis has an important impact on health. Joined to others preventable diseases World Health Organization (WHO)/Pan American Health Organization (PAHO) member countries approved strategies for elimination of Congenital Syphilis in the Americas. This paper aims to describe epidemiological, clinical and treatment characteristics related to 61 patients diagnosed with congenital syphilis in our hospital for the period 1987-2019.

The results of our analysis pointed out an increase in the number of cases in our population with a bimodal curve shape. A high percentage of the mothers did not complete the maternal screening and age at diagnosis was much more in asymptomatic patients. Clinical manifestation denotes a high morbidity in the pediatric population, and the instauration of treatment resolve in most cases the symptoms. We also evaluated the contribution of serological follow up and cerebrospinal fluid study in the diagnosis and therapeutic



Parasitología - Chagas
Hospital de Niños Ricardo Gutiérrez

Centro de Referencia para la Enfermedad de Chagas – Res: 1514/2001



decisions. We concluded that congenital diseases remain a great challenge for clinical practice in our region and requires attention and effort in order to prevent sequelae.

Thank you for considering our manuscript, which has not been published or submitted elsewhere. We believe that our study provides data about different aspects of the presentation of this disease in our population during a large period of time and offers important information related to follow-up as well as missed diagnostic and therapeutic opportunities.

Sincerely,

Dr. Jaime Altcheh
Parasitología
Htal. Niños R. Gutiérrez
M.N. 71997

Jaime Altcheh

Parasitology and Chagas Service, Buenos Aires Children´s Hospital R Gutierrez

Gallo 1330, (1425) Buenos Aires, Argentina.

Tel/fax: +5411-4964-4122

Email: binlugarcia@gmail.com

1 **Title**

2 Congenital syphilis in Argentina: experience in a pediatric hospital

3 **Authors**

4 Luciana Noemí García^{1,2} ¶*, Alejandra Destito Solján¹ ¶, Nicolas Falk^{1,2}, Nicolás Leonel
5 Gonzalez¹, Griselda Ballering¹, Facundo García Bournissen^{1,2}, Guillermo Moscatelli^{1,2},
6 Samanta Moroni¹, Jaime M Altcheh^{1,2}

7 ¹ Servicio Parasitología- Chagas. Hospital de Niños Ricardo Gutierrez, Capital Federal,
8 Buenos Aires, Argentina.

9 ² Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP),
10 CONICET, Buenos Aires, Argentina

11 * Corresponding author:

12 MD, PhD. Luciana N García,

13 Servicio Parasitología- Chagas. Hospital de Niños Ricardo Gutierrez. Gallo 1330,
14 C1425EFD, Buenos Aires, Argentina Tel/FAX: 54 011. 4964-4122. E-mail:
15 binlugarcia@gmail.com

16 ¶ These authors contributed equally to this work.

17 **Abstract**

18 Although congenital syphilis (CS) is preventable, it is still an important health problem
19 worldwide. Recently, an increase in the number of primary and congenital syphilis cases

20 has been observed. Fetal infection can be particularly aggressive, but newborns can be
21 asymptomatic at birth and run the risk of developing systemic compromise with a poor
22 prognosis.

23 We conducted a study (1987-2019) analyzing the medical records of CS diagnosis
24 cases assisted at the Buenos Aires Children' Hospital. Sixty-one patients were included.
25 Information about demographics, clinical and laboratory findings, *T. pallidum* serology
26 and treatment was collected. Median age at diagnosis was 2 months (IQ 1-6 months).
27 The distribution of cases showed a bimodal curve, with a peak in 1993 and in 2017. The
28 main clinical findings were: bone alterations in 36/61 (59%); hepatosplenomegaly in
29 33/61 (54.1%); anemia in 32/51 (62.8%); skin lesions 26/61 (42.6%) and renal
30 compromise in 15/45 (33.3%). Cerebrospinal fluid was studied in 50/61 (81.9%); 5 (10%)
31 were abnormal (reactive VDRL and/or cell alteration count). Only 23 (60.5%) patients
32 had nontreponemal titers fourfold higher than their mothers did. Intravenous penicillin G
33 for an average of 10-14 days was prescribed in 60/61 subjects and one patient received
34 ceftriaxone. Remarkably, only 28 (46%) mothers were tested for syphilis during
35 pregnancy.

36 During follow-up, a decrease in RPR titers was observed reaching seroconversion in
37 31/34 (91%) subjects at a median of 19.2 months after treatment. Treponemal titers
38 (TPHA) remained reactive.

39 Our results highlighted that an increase in the number of cases of CS is occurring in our
40 population with high morbidity related to delayed diagnosis. A good therapeutic
41 response was observed.

42 CS requires a greater effort from obstetricians to adequately screen for the disease
43 during pregnancy and pediatricians should be alert in order to detect cases earlier, to
44 provide an adequate diagnosis and treatment of CS.

45 **Author Summary**

46 CS is caused by mother-to child transmission. Although screening of pregnant women
47 and treatments are available, new cases are increasing worldwide. We reviewed the
48 medical records of CS-patients assisted in our hospital over the past 30 years. Our
49 results showed that there was an increase in the number of CS cases. At birth, most
50 children were asymptomatic and later developed CS clinical manifestations. Penicillin
51 treatment, and in one case ceftriaxone, was prescribed with a good clinical response.
52 Nevertheless, one infant died, four had persistent kidney disorders and one showed
53 bone sequelae damage. Spinal lumbar puncture did not modify therapeutic decisions.
54 In the follow-up, a decrease in nontreponemal antibodies was observed as a marker of
55 treatment response. We concluded that the detection and treatment of CS remains a
56 great challenge for clinical practice in our region.

57 It is crucial that pediatricians and obstetricians give greater attention and make a greater
58 effort to detect this neglected disease in an attempt to reverse its upwards trend.

59 **Introduction:**

60 Congenital syphilis (CS) is the result of a transplacental infection caused by *Treponema*
61 *pallidum pallidum* (TPA) and affects vulnerable populations with social and economic
62 problems [1]. In 2015, PAHO estimated that there were 22,800 cases of CS with a rate
63 of 1.7 cases per 1,000 live births in Latin America and an incidence of 22,800 new cases

64 in that year [2]. In Argentina the number of syphilis cases has doubled or even tripled in
65 recent years—as a result of an increase in primary syphilis in the population of
66 childbearing age, which has produced an increase in the number of CS cases [3]. In this
67 scenario, adequate screening and treatment of infected mothers is vital to avoid
68 transplacental transmission of TPA. [1] [4]

69 Another window of opportunity for diagnosis of CS is the neonatal and infancy period.
70 Nevertheless, since the diagnosis is based on serological studies the interpretation of
71 results is complex and often confusing due to the passive transplacental transfer of
72 maternal antibodies [4]. The majority of infected newborns are asymptomatic and, if they
73 are not diagnosed and treated, the TPA infection persists silently. The resultant
74 inflammatory response continues in tissues and may develop manifestations of CS
75 months or years later. [5].

76 Our main objective was to describe the medical experience relating to the detection,
77 treatment, clinical and serological evolution of patients with CS assisted in our hospital
78 during the last 30 years.

79 **Methods**

80 A Prospective cohort study with retrospective data collection was conducted in a cohort
81 of pediatric patients with congenital syphilis, between February 1987 and June 2019,
82 assisted at the Servicio de Parasitología-Chagas, Hospital de Niños “Ricardo Gutierrez”,
83 a tertiary care hospital without a maternity unit.

84 Case definition criteria:

85 A) Newborns or infants with reactive TPA serology, mother with syphilis during
86 pregnancy and/or clinical evidence of CS

87 Exclusion criteria: patients with acquired syphilis.

88 Adequate syphilis screening during pregnancy was defined by at least one
89 nontreponemal serological test at the first trimester and another at the third trimester.

90 Demographics, clinical findings, TPA serology, general laboratory, complementary
91 studies, and treatment prescribed data were collected.

92 The serological tests used were the nontreponemal test: Rapid plasma reagin (RPR) or
93 Venereal Disease Research Laboratory (VDRL) and the treponemal test: *Treponema*
94 *pallidum* haemagglutination (TPHA).

95 Maternal data were collected for serological pregnancy control and antibiotic treatment.

96 Descriptive statistics were used for the variables of interest. Continuous variables are
97 presented as means with 95% CI or medians and interquartile range. Categorical
98 variables are represented in percentages. The disappearance kinetics of serum
99 antibodies were analyzed using survival analysis (Kaplan-Meyer). Analyses were
100 performed with R software v3.0 (R Core Team 2018. R Foundation for Statistical
101 Computing, Vienna, Austria. <https://www.R-project.org/>).

102 **Ethics Statement**

103 The Ethics Committee and Review Board of the Hospital de Niños Ricardo Gutierrez
104 approved this study (approval number: DI-2020-159-GCBA-HGNRG).The study is
105 registered in clinical trials.gov (NCT04137601) and adhered to the tenets of the
106 Declaration of Helsinki. As part of our regular clinical practice all patients sign a consent

107 form to their data and/or images used for academic purposes anonymously. In the case
108 of a patients' clinical manifestation picture were performed, previous oral consent was
109 obtained from the parents/guardian of the patients.

110 **Results:**

111 Out of 100 clinical charts analyzed, 61 patients fulfilled inclusion criteria for CS. The
112 remaining 39 were patients with acquired syphilis. The data of complementary studies
113 is summarized in a flowchart in Fig 1.

114 **Fig 1. Flowchart of patient inclusion process and complementary studies.**

115 A bimodal time curve was observed with a peak in 1993 and another in 2017 (Fig 2).

116 **Fig 2. Number of congenital syphilis cases.**

117 Histogram shows registered cases by year.

118 As regards perinatal data, (Table 1), 20.6% of mothers were younger than 20 years of
119 age. Adequate TPA serological control was carried out in only 27/57 (47%) women
120 during pregnancy. Only 4 mothers received penicillin treatment. Three mothers received
121 3 doses of benzathine penicillin in the second trimester and the other one, received two
122 regimens of 3 doses of penicillin ending within the last month of pregnancy. Serological
123 data from 4 mothers were not available: 3 children were adopted and one mother died
124 postpartum.

125 **Table 1 Perinatal data**

Perinatal data		
Pregnancy screening	n	%

Adequate	27	44.3
Uncontrolled pregnancy	27	44.3
Inadequate	3	4.9
No available data	4	6.5
Birth outcome	n	%
Preterm (< 37 weeks)	15	24.6
Low birth weight/ IUGR ^a	15	24.6
Full term babies	31	50.8

126 ^a IUGR: Intrauterine Growth Restriction

127 The median age at diagnosis was 2 months (IQ25-75: 1-6 months), ranging from 1 day
 128 to 8.5 years. Early CS was diagnosed before one month of age in 6 patients, between
 129 one to six months of age in 40 patients, and between 1 to 2 years old in 9 patients. Late
 130 CS was diagnosed in 6 children older than 2 years (Fig 3). In 3 patients congenital
 131 coinfection was detected: cytomegalovirus in 2 patients and hepatitis B in 1. All patients
 132 showed negative HIV serology.

133 **Fig 3. Timeline of the age at diagnosis**

134 Bar chart shows the number of patients diagnosed at different ages and the period
 135 of early and late congenital syphilis.

136 At birth, 48/61 (78%) were asymptomatic. In the following weeks 40/48 developed
 137 symptoms of CS (media: 9.4, 95% CI:3.6-15.1 months) and 8 remained asymptomatic.
 138 These asymptomatic cases were diagnosed at different ages (media: 25.63, 95% CI:6.3-
 139 45) as follows: 2 cases were siblings of an index case, 2 cases by pre-surgical serological

140 testing and 4 by serological screening due to the lack of information about TPA serology
141 at birth.

142 In summary, at diagnosis, 53 (86.8%) CS infants were symptomatic and 8 (13.1%)
143 asymptomatic (Fig 4).

144 **Fig 4. Symptomatic newborn**

145 (A) Term male newborn, adequate for gestational age with widespread
146 erythroderma, vesiculobullous eruptions and desquamation (pemphigus
147 syphiliticus). (B) Bone involvement lesions in the same patients are showed:
148 periosteal detachment (arrow).

149 Demographic data as well as clinical findings at diagnosis are presented in Table 2. Our
150 hospital is a pediatric referral center without a maternity unit. The analysis of the place
151 of residence showed that only 11 (18%) lived in Buenos Aires City, 41(67.3%) in nearby
152 cities and 3 (5%) came from neighboring countries. In 6 (9.8%) cases data was not
153 available. Low socioeconomic resources and limited access to the health system were
154 registered in the assisted population.

155 As regards clinical findings, the majority of patients, 49 (80.3%), showed bone
156 involvement (Fig 5). Parrot's pseudoparalysis of the right upper limb was the most
157 common sign. A considerable proportion of patients presented with
158 hepatosplenomegaly (54.1%) as well as dermatological manifestations (50.8%) (Fig 6).

159 **Fig 5. Representative radiological images of bone involvement and**
160 **Hutchinson's teeth findings**

161 (A) Anteroposterior view radiographs of a female newborn showing lytic image in
162 the distal region of left tibia and humerus with diffuse periosteal reaction (arrow).
163 (B) Radiographs of a male newborn showing lytic image in the proximal region of
164 right the tibia and fibula. (C) Hutchinson's teeth in a 2- years old girl (D)
165 Radiographs showing widespread periostitis of the humerus and tibia (arrow) in a
166 2- years old girl

167 **Fig 6. Representative radiological images of the bone lesions evolution after**
 168 **treatment**
 169 (A) Anteroposterior view radiographs of a 14 month-old girl showing diffuse
 170 periosteal reaction in the left humerus as well as in tibia and fibula (B) Improvement
 171 of the lesions after treatment

172 **Table 2 Demographic and clinical findings at diagnosis**

Age		
Median Range IQ 25-75%	2 months 1 day- 8.5 years 1-6 months	
Sex	n	%
Female	29	47.5
Male	32	52.5
Clinical status at diagnosis (n=61)	n	%
Symptomatic	53	86.8
Asymptomatic	8	13.1
Clinical findings ^a	n	%
Bone involvement	36	59
Periostalgia	36	100
Pseudoparalysis	13	36
Saddle nose	1	2.7
Saber shins	2	5.5
Hepatosplenomegaly	33	54.1
Dermatological manifestations	31	50.8
Maculopapular rash	17	27.8
Palms and soles' rash	17	27.9
Pemphigus	15	24.6
Desquamation lesions	11	18
Jaundice	11	18
Condyloma lata	2	3.3
Snuffles/rhinitis	10	16

Fever	15	24.6
Hutchinson's teeth	1	1.65

173 ^a some patients developed more than one clinical feature or had several laboratory findings
174 Complementary studies at diagnosis are presented in Table 3. Alterations in hepatic
175 parameters were observed in 17/47 (36%) of the patients. Severe anemia, with
176 hemoglobin lower than 7.5 g/l and hemodynamic compromise, which required red blood
177 cell transfusion, was observed in 5/61 (8.2 %). Ocular fundus examination showed
178 alterations in 4/36 (2.4%) patients, with retinal pigmentation (n=2) keratitis (n=1) and
179 brightness alteration of the fovea (n=1). Lumbar puncture was performed in 50/61
180 patients (82%): CSF was altered in 5 (10%) patients, 4 showed reactive VDRL and 1
181 showed a high white blood cell count. In 9 patients (18%) lumbar puncture was
182 traumatic.

183

184 **Table 3 Complementary studies at diagnosis**

Routine laboratory data ^a	n	%
Urinalysis	45	73.7
Normal	30	66.6
Altered	15	33.3
Mild proteinuria	8	17.7
Massive proteinuria	4	8.9
Hematuria	9	20
Leukocyturia	2	4.4
Liver functions	47	77
Normal	30	63.8
Altered	17	36.2
Hyperbilirubinemia.	14	29.7
Alanine transaminase elevation	12	25.5
Complete Blood Count	51	83.6
Anemia	30	58.8
Leukocytosis	16	31.4
Thrombocytopenia	5	9.8
Other diagnostic' work up studies ^a	n	%
Ocular fundus examination	36	59
Normal	32	89
Altered	4	11
Keratitis	1	25
Retinal pigmentation	2	50
Fovea alterations	1	25
Bone Radiological Findings	61	100
Normal	22	36
Altered	36	59
Periostitis	36	59
Osteochondritis/osteomyelitis	6	9.8
Fracture	3	4.9
Osteolytic lesions	2	3.2
Missed diagnosis	3	5
Cranial ultrasound	23	37.7
Normal	23	100
Hearing evaluations	19	31.1
Normal	18	94.7
Abnormal	1	5.3

185 ^a some patients developed more than one clinical feature or had several laboratory findings

186 TPA serology at diagnosis: RPR/VDRL showed median titers of 32 dilution (IQ₂₅₋₇₅: 4 -
187 128), and TPHA showed median titers of 640 dilution (IQ₂₅₋₇₅: 160 - 2560).

188 As regards comparison of mother and child RPR/VDRL titers, 38 binomial samples were
189 available. A considerable number (39.4%) of patients did not reach 4-fold titers more
190 than their mothers and in 21% the titers were the same or even lower. (Table 4)

191 Curiously, in our cohort, one patient (1/61) tested negative for RPR at birth but
192 eventually developed symptoms of late CS (Hutchinson's teeth) and RPR was positive
193 (Fig 6C).

194 **Table 4: Nontreponemal comparative testing in mothers and child**

RPR determination/ Matching	4-fold	2-fold	Equally	Lower
Child vs mother's titers	23 (60.5%)	4 (10.5%)	3 (7.9%)	8 (21%)

195
196 Treatment: in 60/61 subjects, intravenous aqueous crystalline penicillin G for 10-14 days
197 was prescribed. Doses were adjusted to patients' age and weight covering possible
198 involvement of CNS, following national guidelines. One patient started treatment with
199 ceftriaxone 50 mg/kg/day because of suspected sepsis. Upon diagnosis of syphilis, 10
200 days of treatment was completed.

201 Jarisch-Herxheimer reaction (fever and some vasomotor signs) occurred in 9/61
202 (14.7%) patients. Its onset was within 12 hours after treatment with a maximum duration
203 of 36 hours.

204 Overall 47/53 (89%) symptomatic patients recovered after treatment (Fig 7). However,

205 a three-month-old patient with severe anemia, acute kidney failure and sepsis by
206 *Escherichia coli* died. In 4 patients persistent proteinuria was observed as a sequelae
207 of renal involvement and in 1 patient knee arthrosis occurred due to bone damage.

208 **Fig 7. Representative images of dermatological manifestations**

209 (A) Maculopapular rash on the palms and soles in a 4-month-old boy. (B)
210 Improvement of the lesions two days after penicillin treatment in the same patient.

211 Serological follow-up: Serological data for follow-up analysis was available for 34/61
212 patients. The media follow-up time was 14.4 months (95% CI: 5.9-23). A decrease of
213 VDRL/RPR titers was observed reaching seroconversion in 31/34 (91%) subjects at a
214 median time of 19.2 months after treatment follow-up. Seroconversion time was
215 analyzed with the Kaplan-Meier test (Fig 8). A decrease in TPHA titers was also
216 observed and only 2 patients showed seroconversion at 5 years of follow-up.

217 **Fig 8. After treatment follow-up RPR titers in 34 congenital syphilis treated**
218 **patients**

219 Figure shows log titers of RPR changes over time. Dark blue line represents the
220 smooth regression of the data.

221 **Discussion:**

222 Over the last 30 years our service, as a pediatric referral center, assisted over 61
223 patients suffering from CS, which is a potentially eradicable disease. In Argentina an
224 increase in primary syphilis was reported over the last few years [3]. In order to see
225 whether the rising trend of primary syphilis had an impact on the occurrence of CS, we
226 conducted a retrospective analysis of a cohort of assisted CS patients in our hospital.

227 Our results showed an increase in the number of cases of CS in recent years.
228 Interestingly a bimodal curve with a peak of cases in the early 90's was observed and

229 another peak in 2017. A similar trend has been highlighted in several countries [5,6].
230 The first increase was attributed to the new diagnostic definition of CS in 1988 [5], and
231 the second peak was due to an increase in reported cases of primary syphilis in women
232 from 2015 onwards [6,7], a phenomena that has also occurred worldwide [3].

233 Despite the fact that 96% of the births took place in medical centers in our country, a
234 high percentage of women were not adequately screened for syphilis during pregnancy
235 [3,8]. This leads to missed opportunities to prevent the transmission of TPA to the fetus
236 [2,9]. In our study, only 47% of pregnant women completed adequate prenatal
237 serological screening and only four mothers were treated. Unfortunately, we do not have
238 sufficient data to rule out a therapeutic failure of these mothers.

239 The WHO estimate that 27% of CS newborns from untreated mothers showed IUGR,
240 prematurity or are born small for gestational age [4]. In our study a high rate of preterm
241 newborns (24.6%) and low birth weight (24.6%) was observed, as was reported
242 worldwide [10, 11]. A high percentage (73%) of our patients were asymptomatic at birth
243 and developed clinical manifestations of CS within the first 2 years of life. It was
244 estimated that two thirds of untreated asymptomatic newborns would develop CS
245 symptoms in the first 3 to 8 weeks of life and almost all at 3 months of life [4]. A delayed
246 diagnosis was observed in our cohort due to inadequate serological studies during
247 pregnancy, which did not alert health professionals to the presence of CS in
248 asymptomatic newborns.

249 The analysis of the clinical manifestation demonstrated a high morbidity of a preventable
250 disease. Bone involvement was observed in a great number of patients. Bone

251 involvement (particularly osteochondritis) revealed by radiological tests, was the most
252 frequent finding in our study. This proved to be a useful marker of CS; as suggested by
253 others authors [4,12]. Hepatosplenomegaly has also been reported as one of the most
254 common findings [11]. In our study, both hepatosplenomegaly and dermatological
255 manifestations followed in frequency after bone lesions. The high rate of bone
256 involvement observed may be due to the fact that we assist infants with CS more than
257 newborns, given that we are a referral pediatric center without a maternity ward.

258 As regards laboratory findings, hepatitis, jaundice and anemia are well-known
259 manifestations of CS. It has been suggested that this is related to the direct action of
260 TPA causing hepatocellular cholestasis (without anatomical alteration of the bile ducts)
261 [13]. Although 54% of our patients presented with hepatomegaly, only 36% presented
262 with alterations in the hepatic panel. In contrast, anemia was present in a high
263 percentage of patients, requiring blood transfusion in 5/61 cases. These findings are
264 similar to those reported in a previous study by our group [8].

265 In order to evaluate CNS involvement, CSF testing (cell count, protein, and VDRL) has
266 been recommended since neurosyphilis is the manifestation most feared [10,14]. In our
267 study, only 10% (5/50) of patients whose CSF was evaluated showed alterations.
268 However, there are many issues with diagnostic accuracy for example: white-cell count
269 and protein values vary with age; VDRL/RPR antibodies can passively transfer into the
270 CSF, and TPA was detected with normal CSF results.[18].

271 These facts justified a treatment regimen that covers, in dose and time, CNS
272 involvement as was prescribed in our patients. The need for CSF evaluation has been

273 questioned, due to its lack of accuracy in confirming or discarding CNS involvement
274 [10,15]. It was suggested that asymptomatic newborn lumbar puncture examination be
275 avoided [1] [16]. In our study lumbar puncture was of limited usefulness as a result of
276 blood contamination and the low VDRL sensitivity and did not change the therapeutic
277 regimen in our patients. Also no differences in clinical after-treatment evolution was
278 observed between patients with or without CSF evaluation confirming that lumbar
279 puncture did not provide reliable data as a prognostic marker.

280 We observed that 89% of asymptomatic patients recovered after treatment with
281 intravenous aqueous crystalline penicillin G. Although 14.7% showed Jarisch-
282 Herxheimer reaction, these events were self-limiting. One patient received daily
283 intravenous ceftriaxone with a favorable clinical evolution. The possibility of using
284 alternative drugs to penicillin for the treatment of syphilis is a field that needs more
285 research. We believe that ceftriaxone is a good alternative given the worldwide shortage
286 of penicillin [17–19].

287 For the diagnosis of syphilis, a wide range of tests are available but several factors must
288 be considered. Direct identification of TPA by dark field microscopy is not routinely used
289 because it is only useful in symptomatic patients with primary syphilis and has low
290 sensitivity [20]. In CS reactive serological results in newborns and infants results can be
291 confusing due to passive placental transfer of maternal antibodies [20,21]. This often
292 results in unnecessary treatment and hospitalization of asymptomatic newborns with
293 reactive serology from mothers with syphilis, which overloads the health system. Non
294 treponemal antibody titers 4 times higher in newborns than those of the mother has
295 been proposed as a marker of active CS infection [10]. [22]. However in our study, 4-

296 fold higher RPR titers were absent in a considerable proportion of infected patients and
297 did not help to reach CS diagnosis [20].

298 Non-treponemal tests (VDRL/RPR) detect anti-cardiolipin antibodies. The sensitivity of
299 this test increases with higher titers. A higher concentration of VDRL/RPR antibodies is
300 related to the activity of the infection. In our population, a sustained decrease in antibody
301 titers was observed as an indicator of therapeutic response (Fig 4).

302 The treponemal (TPHA, FTA- Abs) test detects TPA antibodies and is used to confirm
303 reactive VDRL/PRP. The contribution of the treponemal (TPHA, FTA-Abs) test in the
304 diagnosis of CS was questioned. In our study TPHA titers remained reactive after
305 treatment so this test was not useful for treatment monitoring.

306 Our results reflect that it is vital to study all asymptomatic newborns whose mothers have
307 syphilis, and to carry out a comprehensive clinical and laboratory evaluation including
308 long bone radiography due to the high incidence of bone compromise observed in CS. If
309 VDRL/RPR becomes negative during follow up, showing the disappearance of passively
310 transferred maternal antibodies, CS diagnosis is ruled out [21]. Maternal-specific
311 treponemal antibodies may persist for up to 12 months [6,10]. If VDRL/RPR remains
312 reactive at 12 months, the infection is confirmed.

313 New techniques for CS diagnosis are needed since a long term follow-up is required to
314 confirm the diagnosis, especially in asymptomatic infants [2]. Nucleic acid- based
315 amplification assays, such as polymerase chain reaction (PCR) have greatly improved
316 sensitivity and specificity of direct detection of TPA. However, there is sparse information
317 regarding TPA-PCR in clinical settings. A clinical study is under development in our center

318 (Clinical trials Identifier: NCT04084379) in order to validate the sensitivity and specificity
319 of this test for CS diagnosis.

320 Low patient adherence to follow up was observed. We assist vulnerable and low-income
321 populations with high internal migration, which generates real-world problems in
322 complying with medical follow-up. This constituted a barriers to adequate follow-up in our
323 cohort.

324 There are many issues that make CS a great challenge for the pediatrician, as is shown
325 in this study. A high number of symptomatic infants with a preventable and a completely
326 curable fetal infection was observed resulting from inadequate detection and treatment
327 of syphilis during pregnancy.

328 It is mandatory to improve the health care of syphilis, both in terms of screening and
329 treatment, during pregnancy.

330 **Acknowledgments:**

331 The authors wish to thank native speaker Lesley Speakman for revising the english of
332 the manuscript.

333 **Bibliography:**

- 334 1. Centers for Disease , Control, Others. Sexually transmitted diseases treatment guidelines,
335 2015. *Ann Emerg Med.* 2015;66: 526–528.
- 336 2. Pan American Health Organization. Framework for Elimination of Mother-to-Child
337 Transmission of HIV, Syphilis, Hepatitis B, and Chagas. Available:
338 [https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-](https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y)
339 [eng.pdf?sequence=1&isAllowed=y](https://iris.paho.org/bitstream/handle/10665.2/34306/PAHOCHA17009-eng.pdf?sequence=1&isAllowed=y)
- 340 3. Boletín E. Boletín sobre el VIH, SIDA e ITS en la Argentina. Ministerio de Salud y Desarrollo

- 341 Social; DICIEMBRE DE 2019. Report No.: N° 36 - AÑO XXII - DICIEMBRE DE 2019.
342 Available: http://www.msal.gob.ar/images/stories/bes/graficos/0000001754cnt-boletin-epidemiologico-2019_vih-sida-its.pdf
343
- 344 4. Read JS, Schleiss MR. Congenital and Perinatal Infections. Oxford University Press; 2017.
345 Available: <https://play.google.com/store/books/details?id=SwpDDwAAQBAJ>
- 346 5. Cooper JM, Sánchez PJ. Congenital syphilis. *Semin Perinatol.* 2018;42: 176–184.
347 doi:10.1053/j.semperi.2018.02.005
- 348 6. Woods CR. Syphilis in children: congenital and acquired. *Semin Pediatr Infect Dis.*
349 2005;16: 245–257. doi:10.1053/j.spid.2005.06.005
- 350 7. Kidd S, Bowen VB, Torrone EA, Bolan G. Use of National Syphilis Surveillance Data to
351 Develop a Congenital Syphilis Prevention Cascade and Estimate the Number of Potential
352 Congenital Syphilis Cases Averted. *Sex Transm Dis.* 2018;45: S23–S28.
353 doi:10.1097/OLQ.0000000000000838
- 354 8. Altcheh J, Lapunzina P, Freilij H. Sifilis connatal. *Arch Argent Pediatr.* 1994;92: 2–7.
355 Available: <https://www.sap.org.ar/publicaciones/archivos/numeros-anteriores/75/Febrero-1994.html>
356
- 357 9. Schmid GP, Stoner BP, Hawkes S, Broutet N. The need and plan for global elimination of
358 congenital syphilis. *Sex Transm Dis.* 2007;34: S5–10.
359 doi:10.1097/01.olq.0000261456.09797.1b
- 360 10. Heston S, Arnold S. Syphilis in Children. *Infect Dis Clin North Am.* 2018;32: 129–144.
361 doi:10.1016/j.idc.2017.11.007
- 362 11. Dorfman DH, Glaser JH. Congenital syphilis presenting in infants after the newborn period.
363 *N Engl J Med.* 1990;323: 1299–1302. doi:10.1056/NEJM199011083231902
- 364 12. Brion LP, Manuli M, Rai B, Kresch MJ, Pavlov H, Glaser J. Long-bone radiographic
365 abnormalities as a sign of active congenital syphilis in asymptomatic newborns. *Pediatrics.*
366 1991;88: 1037–1040. Available: <https://www.ncbi.nlm.nih.gov/pubmed/1945608>
- 367 13. Pizzarossa AC, Rebella M. Hepatitis in patients with syphilis: an overlooked association.
368 *BMJ Case Rep.* 2019;12. doi:10.1136/bcr-2018-226918
- 369 14. Ropper AH. Neurosyphilis. *New England Journal of Medicine.* 2019. pp. 1358–1363.
370 doi:10.1056/nejmra1906228
- 371 15. Michelow IC, Wendel GD Jr, Norgard MV, Zeray F, Leos NK, Alsaadi R, et al. Central
372 nervous system infection in congenital syphilis. *N Engl J Med.* 2002;346: 1792–1798.
373 doi:10.1056/NEJMoa012684
- 374 16. Workowski KA, Berman SM. Centers for Disease Control and Prevention Sexually
375 Transmitted Disease Treatment Guidelines. *Clin Infect Dis.* 2011;53 Suppl 3: S59–63.
376 doi:10.1093/cid/cir694
- 377 17. Taylor MM, Zhang X, Nurse-Findlay S, Hedman L, Kiarie J. The amount of penicillin
378 needed to prevent mother-to-child transmission of syphilis. *Bull World Health Organ.*
379 2016;94: 559–559A. doi:10.2471/BLT.16.173310

- 380 18. Nurse-Findlay S, Taylor MM, Savage M, Mello MB, Saliyou S, Lavayen M, et al. Shortages
381 of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An
382 evaluation from multi-country surveys and stakeholder interviews. *PLoS Med.* 2017;14:
383 e1002473. doi:10.1371/journal.pmed.1002473
- 384 19. Katanami Y, Hashimoto T, Takaya S, Yamamoto K, Kutsuna S, Takeshita N, et al.
385 Amoxicillin and Ceftriaxone as Treatment Alternatives to Penicillin for Maternal Syphilis.
386 *Emerg Infect Dis.* 2017;23: 827–829. doi:10.3201/eid2305.161936
- 387 20. Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital
388 syphilis: an overview. *Bull World Health Organ.* 2004;82: 439–446. Available:
389 <https://www.ncbi.nlm.nih.gov/pubmed/15356937>
- 390 21. Woods CR. Congenital syphilis-persisting pestilence. *Pediatr Infect Dis J.* 2009;28: 536–
391 537. doi:10.1097/INF.0b013e3181ac8a69
- 392 22. Matthias JM, Rahman MM, Newman DR, Peterman TA. Effectiveness of Prenatal
393 Screening and Treatment to Prevent Congenital Syphilis, Louisiana and Florida, 2013-
394 2014. *Sex Transm Dis.* 2017;44: 498–502. doi:10.1097/OLQ.0000000000000638
- 395 23. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey
396 AB, et al. Screening for Syphilis Infection in Pregnant Women: US Preventive Services
397 Task Force Reaffirmation Recommendation Statement. *JAMA.* 2018;320: 911–917.
398 doi:10.1001/jama.2018.11785

399 **Supporting information:**

400 **S1 File. STROBE checklist.**




Figure 2

